Intracellular localization of AMP deaminase and its novel role in BCAA and lipid metabolism in diabetic cardiomyopathy

Background A metabolomic study in the human heart suggested a pivotal role of amino acid (AA) metabolism in fatty acid oxidation, which is dysregulated in type 2 diabetes mellitus (T2DM) and heart failure. We previously reported that aberrant up-regulation of AMP deaminase 3 (AMPD3) impairs cardiac energetics in T2DM hearts, and AMPD3 was recently shown to be activated by fasting and to promote AA metabolism and fatty acid oxidation in skeletal muscle. A sodium glucose cotransporter 2 inhibitor (SGLT2i) has been shown to augment systemic AA metabolism, but its effect on cardiac AA metabolism remains unknown. Purpose We hypothesized that AMPD3 has a role in AA and lipid metabolism in cardiomyocytes and that the protective effect of an SGLT2i in diabetic hearts is mediated by modification of AA and lipid metabolism. Methods and results Proteomic analyses of AMPD3 immunoprecipitates in rat hearts revealed that AMPD3 interacted with the E1α and E2 components of the BCKDH complex, a rate-limiting enzyme of branched-chain AA (BCAA) catabolism. Immunoblotting using subcellular fractions revealed that BCKDH localized not only in the mitochondria matrix but also in the cytosol and endoplasmic reticulum (ER) and that AMPD3 interacted with BCKDH in the cytosol and ER. Despite comparable expression of BCKDH components and phosphorylation of E1α at Ser293, significant accumulation of BCAA was observed in T2DM rats (OLETF; 317±30 nmol/g) compared to that in control rats (LETO; 213±16 nmol/g), and the accumulation of BCAA was accompanied by up-regulation of AMPD3 in the cytosol and ER by 98% and 231%, respectively. In cardiomyocytes, disruption of BCAA catabolism by knockdown of BCKDH-E1α resulted in a 5.8-fold increase in AMPD3 at the transcriptional level and blunted lipid droplet biogenesis in response to a long-chain fatty acid challenge. Next, myocardial infarction (MI) was induced in LETO and OLETF pretreated with empagliflozin (10 mg/kg/day, 14 days) or a vehicle. Pathway analysis of cardiac metabolites revealed arginine biosynthesis and BCAA metabolism as the most significantly changed pathways with empagliflozin, with BCAA (791±187 nmol/g), glutamate, glutamine and urea being significantly increased. Empagliflozin restored myocardial ATP and survival after MI in OLETF to levels comparable to those in LETO. Electron microscopy showed a significantly higher prevalence of myocardium lipid droplets in OLETF, which was further increased by empagliflozin. Conclusions The results support the hypotheses that imbalance of extra-mitochondrial AMPD3-BCKDH interaction underlies dysregulated BCAA metabolism in T2DM hearts and that activation of cardiac AA metabolism by an SGLT2i normalizes fatty acid overload through sequestration into intracellular lipid droplets. FUNDunding Acknowledgement Type of funding sources: Foundation. Main funding source(s): Boehringer Ingelheim

Metabolic buffer analysis reveals the simultaneous, independent control of ATP and adenylate energy ratios

Determining the underlying principles behind biological regulation is important for understanding the principles of life, treating complex diseases and creating de novo synthetic biology. Buffering—the use of reservoirs of molecules to maintain molecular concentrations—is a widespread and important mechanism for biological regulation. However, a lack of theory has limited our understanding of its roles and quantified effects. Here, we study buffering in energy metabolism using control theory and novel buffer analysis. We find that buffering can enable the simultaneous, independent control of multiple coupled outputs. In metabolism, adenylate kinase and AMP deaminase enable simultaneous control of ATP and adenylate energy ratios, while feedback on metabolic pathways is fundamentally limited to controlling one of these outputs. We also quantify the regulatory effects of the phosphagen system—the above buffers and creatine kinase—revealing which mechanisms regulate which outputs. The results are supported by human muscle and mouse adipocyte data. Together, these results illustrate the synergy of feedback and buffering in molecular biology to simultaneously control multiple outputs.

Activity of purine nucleotide catabolic enzymes in the liver of rats under conditions of nutritional imbalance

The aim of the study was to investigate the activity of purine nucleotide catabolism enzymes, in particular, AMP-deaminase, 5'-nucleotidase, guanosine deaminase, and guanosine phosphorylase and xanthine oxidase in the cytosolic fraction of the liver of rats under conditions of different dietary supply of sucrose and dietary proteins. Enzyme activity was determined by photo colorimetric method: AMP-deaminase activity by the amount of ammonia formed by deamination of AMP, which has a maximum absorption at λ-540 nm and 5'-nucleotidase activity by the amount of Pn formed by hydrolysis of AMP at λ-8. The activity of guanosine phosphorylase, guanosine deaminase and xanthine oxidase was determined by spectrophotometric method. The results of studies have shown that due to consuming a high-sucrose diet in on the background of protein deficiency, the activation of purine nucleotide catabolism is observed and it can lead to disruption of the regulation of energy-dependent processes in liver cells. A critical factor influencing on the state of the purine nucleotide system and the activity of enzymes of their catabolism is alimentary protein deficiency.

Novel regulation of cardiac branched-chain amino acid metabolism through AMP deaminase: a possible therapeutic target for diabetic cardiomyopathy

Background Dysregulation of branched-chain amino acid (BCAA) metabolism has been shown to be associated with type 2 diabetes mellitus (T2DM) and heart failure. BCAA reportedly protects cells from fatty acid-induced mitochondrial injury via sequestration of fatty acids in intracellular lipid droplets from mitochondria. We previously reported that up-regulation of AMP deaminase 3 (AMPD3) impairs cardiac energetics in T2DM hearts, and AMPD3 was recently shown to participate in regulation of amino acid metabolism in skeletal muscle. Purpose We hypothesized that AMPD3 regulates cardiac amino acid metabolism by interaction with branched-chain α-ketoacid dehydrogenase (BCKDH) complex and that cardioprotective effect of sodium glucose cotransporter 2 inhibitors is mediated by modification of BCAA metabolism in diabetic cardiomyocytes. Methods and results Proteomic analyses of immunoprecipitates with an anti-AMPD3 antibody in rat hearts revealed that AMPD3 interacted with the E1α component of BCKDH complex. Whereas BCKDH has been reported to localize in mitochondria matrix as a rate-limiting enzyme for BCAA catabolism, immunoblotting using subcellular fractions revealed that BCKDH E1α is present in cytosol and endoplasmic reticulum as well. AMPD3-BCKDH E1α interaction was decreased by 68% in T2DM rats (OLETF) compared to that in control rats (LETO), and significant accumulation of BCAAs was observed in OLETF hearts (317±30 vs. 213±16 nmol/g). Survival rate at 48 hours after myocardial infarction (MI) was significantly lower in OLETF than in LETO (40% vs 84%). Empagliflozin treatment (10 mg/kg/day, 14 days) before MI improved the survival rate in OLETF to 70%, increased BCAAs as the top of 92 detected metabolites (791±187 nmol/g) and significantly preserved tissue ATP in the non-MI remote region. Electron microscopy showed a significantly higher prevalence of myocardium lipid droplets in OLETF, which was further increased by empagliflozin. Conclusions Results of the present analyses support the hypotheses that conversion of BCAA-derived branched-chain α-ketoacid to branched-chain acyl-CoA is suppressed by reduced AMPD3-BCKDH interaction in the myocardium of T2DM and that empagliflozin induces compensation of the dysregulated cardiac BCAA metabolism by augmentation of BCAA influx and promotion of fatty acid sequestration in intracellular lipid droplets. Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): Boehringer Ingelheim

Adenosine monophosphate deaminase 3 null mutation causes reduction of naive T cells in mouse peripheral blood

Adenosine monophosphate deaminase 3 (Ampd3) encodes the erythrocyte isoform of the adenosine monophosphate (AMP) deaminase gene family. Mutations in this gene have been reported in humans, leading to autosomal-recessive erythrocyte AMP deaminase deficiency. However, the mutation is considered clinically asymptomatic. Using N-ethyl-N-nitrosourea mutagenesis to find mutations that affect peripheral lymphocyte populations, we identified 5 Ampd3 mutations (Ampd3guangdong, Ampd3carson, Ampd3penasco, Ampd3taos, and Ampd3commanche) that strongly correlated with a reduction in naive CD4+ T and naive CD8+ T-cell populations. Causation was confirmed by targeted ablation of Ampd3. Knockout mice had reduced frequencies of CD62LhiCD44lo CD4+ naive and CD8+ naive T cells. Interestingly, these phenotypes were restricted to T cells circulating in peripheral blood and were not seen in T cells from secondary lymphoid organs (lymph nodes and spleen). We found that reduction of naive T cells in the peripheral blood of Ampd3−/− mice was caused by T-cell–extrinsic factor(s), which we hypothesize to be elevated levels of adenosine triphosphate released by Ampd3-deficient erythrocytes. These findings provide an example in which disruption of an erythrocyte-specific protein can affect the physiological status of lymphocytes in peripheral blood.

Metabolic Buffer Analysis Reveals the Simultaneous, Independent Control of ATP and Adenylate Energy Ratios

Determining the underlying principles behind biological regulation is important for understanding the principles of life, treating complex diseases, and creating de novo synthetic biology. Buffering - the use of reservoirs of molecules to maintain molecular concentrations - is a widespread and important mechanism for biological regulation. However, a lack of theory has limited our understanding of its roles and quantified effects. Here, we study buffering in energy metabolism using control theory and novel buffer analysis. We find that buffering can enable the simultaneous, independent control of multiple coupled outputs. In metabolism, adenylate kinase and AMP deaminase enable simultaneous control of ATP and adenylate energy ratios, while feedback on metabolic pathways is fundamentally limited to controlling one of these outputs. We also quantify the regulatory effects of the phosphagen system - the above buffers and creatine kinase - revealing which mechanisms regulate which outputs. The results are supported by human muscle and mouse adipocyte data. Together, these results illustrate the synergy of feedback and buffering in molecular biology to simultaneously control multiple outputs.